Wednesday, July 8, 2026

Drug profile · INN

pinacidil

pinacidil (PINDAC) is a sulfonylurea receptor 2, kir6.2 opener. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — pinacidil
US status
approved
Class
Route
ORAL
Patents
0
Programs
0
Data quality
0.84

Quick answer

pinacidil (PINDAC) is a sulfonylurea receptor 2, kir6.2 opener. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN pinacidil
Brand PINDAC
Mechanism Sulfonylurea receptor 2, Kir6.2 opener
Target Sulfonylurea receptor 2, Kir6.2
Route ORAL
Formulation CAPSULE, EXTENDED RELEASE

Mechanism of action

Sulfonylurea receptor 2, Kir6.2 opener

Primary target: Sulfonylurea receptor 2, Kir6.2

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. minoxidil Sulfonylurea receptor 2, Kir6.2 opener

Frequently asked questions

What is pinacidil?

pinacidil (PINDAC) is a sulfonylurea receptor 2, kir6.2 opener. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for pinacidil?

PINDAC is a marketed brand name for pinacidil. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of pinacidil?

pinacidil has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.